ClinicaliQ Trial Snapshot
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07363694.
- Treatment being tested: PF-07275315, a novel investigational medicine, is being evaluated for efficacy and safety in patients with moderate to severe COPD to address the significant unmet need in respiratory disease management.
- Patient eligibility overview: The trial focuses on adults with confirmed moderate to severe COPD, a progressive airway obstruction condition that substantially impacts breathing and quality of life, representing a substantial proportion of the UK's respiratory disease burden.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 35 to 80 years old * Have had moderate-to-severe COPD for at least 12 months * Have a documented history of at least 2 moderate or severe exacerbations within the last 12 months…
Eligibility Snapshot
- Key Inclusion Criteria: * Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition). * Spirometry values (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] less than [
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.